CTOs on the Move

Shire plc

www.nrpharma.com

 
Shire plc is a Radford, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Carondelet Medical Group

Carondelet Medical GroupPatient Centered Care, Experienced Medical ExcellenceThe Carondelet team is here to provide exceptional, patient-centered medical care for the entire family. From routine check-ups to chronic disease management to healing from a...

DRX

DRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LimaCorporate

LimaCorporate is a medical device company. LimaCorporate’s product range includes Large Joint Primary and Revision implants, Extremities and Fixation solutions and dedicated Patient-Specific prostheses division.

Janssen

Janssen, a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.